全文获取类型
收费全文 | 84870篇 |
免费 | 5546篇 |
国内免费 | 3078篇 |
专业分类
耳鼻咽喉 | 826篇 |
儿科学 | 2016篇 |
妇产科学 | 1582篇 |
基础医学 | 20126篇 |
口腔科学 | 1211篇 |
临床医学 | 6454篇 |
内科学 | 15764篇 |
皮肤病学 | 1111篇 |
神经病学 | 3520篇 |
特种医学 | 1761篇 |
外国民族医学 | 12篇 |
外科学 | 4130篇 |
综合类 | 10255篇 |
预防医学 | 11174篇 |
眼科学 | 870篇 |
药学 | 6914篇 |
31篇 | |
中国医学 | 1404篇 |
肿瘤学 | 4333篇 |
出版年
2023年 | 1018篇 |
2022年 | 1462篇 |
2021年 | 2737篇 |
2020年 | 2827篇 |
2019年 | 2303篇 |
2018年 | 2217篇 |
2017年 | 2500篇 |
2016年 | 2564篇 |
2015年 | 3082篇 |
2014年 | 5063篇 |
2013年 | 5288篇 |
2012年 | 4830篇 |
2011年 | 5683篇 |
2010年 | 4546篇 |
2009年 | 4377篇 |
2008年 | 4395篇 |
2007年 | 4367篇 |
2006年 | 3881篇 |
2005年 | 3391篇 |
2004年 | 2979篇 |
2003年 | 2664篇 |
2002年 | 2100篇 |
2001年 | 2008篇 |
2000年 | 1706篇 |
1999年 | 1480篇 |
1998年 | 1294篇 |
1997年 | 1277篇 |
1996年 | 1107篇 |
1995年 | 1244篇 |
1994年 | 1173篇 |
1993年 | 945篇 |
1992年 | 826篇 |
1991年 | 709篇 |
1990年 | 643篇 |
1989年 | 556篇 |
1988年 | 525篇 |
1987年 | 429篇 |
1986年 | 338篇 |
1985年 | 598篇 |
1984年 | 482篇 |
1983年 | 328篇 |
1982年 | 295篇 |
1981年 | 266篇 |
1980年 | 217篇 |
1979年 | 180篇 |
1978年 | 137篇 |
1977年 | 100篇 |
1976年 | 93篇 |
1974年 | 50篇 |
1973年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Advances in vaccinia virus-based vaccine vectors,with applications in flavivirus vaccine development
《Vaccine》2022,40(49):7022-7031
Historically, virulent variola virus infection caused hundreds of millions of deaths. The smallpox pandemic in human beings has spread for centuries until the advent of the attenuated vaccinia virus (VV) vaccine, which played a crucial role in eradicating the deadly contagious disease. Decades of exploration and utilization have validated the attenuated VV as a promising vaccine vehicle against various lethal viruses. In this review, we focus on the advances in VV-based vaccine vector studies, including construction approaches of recombinant VV, the impact of VV-specific pre-existing immunity on subsequent VV-based vaccines, and antigen-specific immune responses. More specifically, the recombinant VV-based flaviviruses are intensively discussed. Based on the publication data, this review aims to provide valuable insights and guidance for future VV-based vaccine development. 相似文献
3.
4.
Ahmad Adebayo Irekeola Engku Nur Syafirah E.A.R. Yusuf Wada Rohimah Mohamud Norhafiza Mat Lazim Chan Yean Yean Rafidah Hanim Shueb 《Indian journal of medical microbiology》2022,40(3):420-426
BackgroundEpstein-Barr virus (EBV) is a member of the herpesvirus family that is known to ubiquitously infect people worldwide. However, the actual prevalence of EBV infection in diseased patients in Nigeria, remains unknown. This study was thus conducted to ascertain the true prevalence.MethodsA systematic review and meta-analysis of published data was conducted according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Electronic databases including PubMed, Scopus, ScienceDirect, and Google Scholar were searched for studies reporting the occurrence of EBV infection among patients with established diseases. Studies were included if they assessed EBV infection in diseased patients in Nigeria. Data were extracted and subsequently analysed using R software. Funnel plot and Egger's regression test was used to assess publication bias, while JBI prevalence tool was used to assess study quality.ResultsA total of 13 studies covering 228 cases of EBV infection among 1157 diseased patients were included. Summary estimates were computed using random-effects model. The pooled prevalence of EBV infection was 20.3% (95% CI: 10.8–34.9, I2 ?= ?92.26, p ?< ?0.001). When stratified according to the type of disease, higher estimates were obtained for patients suffering from Kaposi's sarcoma (98.7%, 95% CI: 82.2–99.9) and Nasopharyngeal malignancy (85.7%, 95% CI: 70.0–93.9). A prevalence of 13.4% (95% CI: 6.0–27.4) and 12.2% (95% CI: 4.8–27.8) was derived for the most reported patient populations, lymphoma and HIV, respectively.ConclusionThis first meta-analysis on the prevalence of EBV among Nigerian patients suffering from various diseases reveals a prevalence that emphasises the need to routinely monitor EBV infection in all EBV-associated diseases in Nigeria. 相似文献
5.
6.
The circadian rhythm in humans is determined by the central clock located in the hypothalamus’s suprachiasmatic nucleus, and it synchronizes the peripheral clocks in other tissues. Circadian clock genes and clock-controlled genes exist in almost all cell types. They have an essential role in many physiological processes, including lipid metabolism in the liver, regulation of the immune system, and the severity of infections. In addition, circadian rhythm genes can stimulate the immune response of host cells to virus infection. Hepatitis B virus (HBV) infection is the leading cause of liver disease and liver cancer globally. HBV infection depends on the host cell, and hepatocyte circadian rhythm genes are associated with HBV replication, survival, and spread. The core circadian rhythm proteins, REV-ERB and brain and muscle ARNTL-like protein 1, have a crucial role in HBV replication in hepatocytes. In addition to influencing the virus’s life cycle, the circadian rhythm also affects the pharmacokinetics and efficacy of antiviral vaccines. Therefore, it is vital to apply antiviral therapy at the appropriate time of day to reduce toxicity and improve the effectiveness of antiviral treatment. For these reasons, understanding the role of the circadian rhythm in the regulation of HBV infection and host responses to the virus provides us with a new perspective of the interplay of the circadian rhythm and anti-HBV therapy. Therefore, this review emphasizes the importance of the circadian rhythm in HBV infection and the optimization of antiviral treatment based on the circadian rhythm-dependent immune response. 相似文献
7.
8.
异质性耐药是一种特殊的细菌耐药类型,常表现为同一克隆来源的不同细菌亚群对某种抗菌药物表现出不一致的耐药特征,大多数亚群对某种抗菌药物敏感,而少部分亚群对其耐药或高度耐药。异质性耐药分离株常会导致特定抗菌药物抗感染治疗失败。针对异质性耐药菌较为深入的研究主要集中于革兰阴性菌,革兰阳性球菌的相关报道较少。近年有研究报道万古霉素、利奈唑胺、苯唑西林等多种类型抗菌药物异质性耐药金黄色葡萄球菌分离株出现,但其实际临床意义尚待进一步评估。此文对金黄色葡萄球菌异质性耐药机制和检测技术最新进展进行综述,为细菌异质性耐药机制研究和新型检测技术研发提供新的思路。 相似文献
9.
《Seminars in perinatology》2022,46(7):151635
The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) maintains a database of extremely preterm infants known as the Generic Database (GDB). Begun in 1987, this database now includes more than 91,000 infants, most of whom are extremely preterm (<29 weeks gestation). The GDB has been the backbone of the NRN, providing high quality, prospectively collected data to study the changing epidemiology of extreme prematurity and its outcomes over time. In addition, GDB data have been used to generate hypotheses for prospective studies and to develop new clinical trials by providing information about the numbers and characteristics of available subjects and the expected event rates for conditions and complications to be studied. Since its inception, the GDB has been the basis of more than 200 publications in peer-reviewed journals, many of which have had a significant impact on the field of neonatology. 相似文献
10.
《Vaccine》2022,40(33):4889-4896
BackgroundDuring the COVID-19 pandemic, the number of hepatitis B virus (HBV) vaccinations among men who have sex with men (MSM) has been considerably lower than before the pandemic. Moreover, less frequent HBV testing and a reduction in numbers of sex partners have been reported. We assessed the impact of these COVID-19-related changes on HBV transmission among MSM in the Netherlands.MethodsWe estimated the changes in sexual activity, HBV testing, and HBV vaccination among MSM during the pandemic from Dutch data. We used a deterministic compartmental model and investigated scenarios with small or large declines in sexual activity, testing, and vaccination for the current phase of the pandemic (without available data). We examined the increase in HBV vaccinations needed to prevent further increase in HBV incidence.ResultsWith a decrease in numbers of sex partners of 15–25% during the first lockdown and 5% during the second lockdown, we found a decline of 6.6% in HBV incidence in 2020, despite a >70% reduction in HBV testing and vaccination during the first lockdown. With numbers of sex partners rebounding close to pre-pandemic level in 2021, and a reduction of 15% in testing and 30% in vaccination in 2021, we found an increase of 1.4% in incidence in 2021 and 3.1% in 2026. With these changes, an increase of ≥60% in HBV vaccinations in 2022 would be needed to bring the HBV incidence in 2023 back to the level that it would have had if the COVID-19-related changes had not occurred.ConclusionsDespite reductions in sexual activity during the COVID-19 pandemic, the decrease in HBV vaccinations may result in a small increase in HBV incidence after 2021, which may persist for years. It is important to restore the vaccination level and limit further increase in HBV transmission among MSM. 相似文献